Global Journal of Veterinary Medicine and Research

Opinion Article - Global Journal of Veterinary Medicine and Research ( 2022) Volume 10, Issue 1

Biophosphonates uses in veterinary medicine

Philip Odunayo*
Department of Veterinary Physiology and Pharmacology, Texas A&M University, TX, USA
*Corresponding Author:
Philip Odunayo, Department of Veterinary Physiology and Pharmacology, Texas A&M University, TX, USA, Email:

Received: 07-Feb-2022, Manuscript No. GJVMR-22-59199; Editor assigned: 09-Feb-2022, Pre QC No. GJVMR-22-59199 (R); Reviewed: 24-Feb-2022, QC No. GJVMR-22-59199; Revised: 04-Mar-2022, Manuscript No. GJVMR-22-59199 (R); Published: 11-Mar-2022, DOI: 10.15651/GJVMR.22.10.005


Bisphosphonates (BP) are characterized by their ability to bind strongly with bone minerals and inhibit bone resorption. However, BP has a wide range of pharmacological activities in addition to inhibition of bone resorption, including inhibition of cancer cell metastasis and angiogenesis, and inhibition of proliferation and death in vitro. In addition, inhibition of background metalloproteinase activity, altered expression of cytokines and growth factors, and reduction of pain parameters have also been reported. In humans, clinical use of BP has transformed the treatment of postmenopausal osteoporosis, rare bone diseases such as osteogenesis imperfecta, as well as multiple myeloma and breast cancer and prostate metastases, are not uncommon but have significant side effects.

Bisphosphonates are potent antiallergic agents that may adversely affect bone healing in jockeys and normal bone adaptation in young racehorses. There is concern that inhibiting bisphosphonates of normal bone metabolism may lead to increased fractures during intense exercise. We found only one report describing tiludronate concentrations in equine bones and no studies describing clodronate. Knowing the residence time in bone may help better understand the long-term effects of these compounds. Our aim was to develop a method for the detection of bisphosphonates in bone and to add to the limited information available on the handling of these drugs in equine bone.

Two horses received clodronate and 2 tiludronate disodium. Postmortem collection of bones and teeth occurred either 4 or 30 d post drug administration. Additionally, postmortem blood, synovial fluid, aqueous humor, and bone samples from racehorses with various histories of bisphosphonate administration were collected, and concentrations determined using the developed LCMS/MS method. Bisphosphonates were detected in bones and teeth tested at 4 and 30 d. In a postmortem postmortem sample, clodronate was detected in bone from a horse with reported administration 18 mo prior; clodronate was not detected in other sample types collected from this horse. Bisphosphonates persist in bone for long periods of time, which can lead to potential long-term effects, increasing fracture risk in young and/or athletic horses.

Despite the well-characterized fitness advantages of BP use in humans, the evidence-base for the healing efficacy of BPs in veterinary medication is, through comparison, limited. Notwithstanding, BPs are used extensively in small animal veterinary exercise for the scientific control of hyperparathyroidism, idiopathic hypercalcemia in cats, in addition to for the palliative care of bone tumors which might be not unusual place in dogs, and in particular, number one bone tumors together with osteosarcoma. Palliative BP remedy has additionally currently elevated in veterinary oncology to relieve tumor-related bone pain. In equine veterinary exercise, non-nitrogen-containing BPs are FDA-permitted to manipulate scientific symptoms and symptoms related to navicular syndrome in grownup horses. However, there are developing worries concerning the off-label use of BPs in juvenile horses. Here we speak the cutting-edge expertise of the strengths, weaknesses and cutting-edge controversies surrounding BP use in veterinary medication to spotlight the destiny software of those probably useful drugs.

One bisphosphonate, disodium clodronate, was selected as the bisphosphonate for this study due to its ubiquity and ease of use. It, like the others, is not approved for use in young horses. Other bisphosphonates are labeled for use in horses older than 4 years for the treatment of degenerative bone disorders.

Bisphosphonates are used to treat osteoporosis and similar diseases that cause loss of bone density in humans and animals,” she says. "However, these drugs are widely used 'off-label' in all ages of horses, and our particular concern is their off-label use in ponies."